Table 2.
Clinicopathological characteristics and TLR 5, 7, and 9 expression
| TLR 5 | P | TLR 7 | P | TLR 9 | P | Missing | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | |||||
| Sex | |||||||||||||||
| Male | 46 (30.7) | 28 (18.7) | 54 (36.0) | 22 (14.7) | 35 (23.3) | 60 (40.0) | 55 (36.7) | 5 (3.3) | 24 (16.0) | 70 (46.7) | 51 (34.0) | ||||
| Female | 13 (25.0) | 9 (17.3) | 22 (42.3) | 8 (15.4) | 0.432* | 12 (23.1) | 26 (50.0) | 14 (26.9) | 0.433* | 4 (7.7) | 6 (11.5) | 22 (42.3) | 20 (38.5) | 0.947* | 0 |
| Agea | |||||||||||||||
| Lowest 1/3 | 19 (28.4) | 14 (20.9) | 25 (37.3) | 9 (13.4) | 15 (22.4) | 24 (35.8) | 28 (41.8) | 2 (3.0) | 15 (22.4) | 31 (44.8) | 19 (28.4) | ||||
| Middle 1/3 | 18 (26.5) | 12 (17.6) | 27 (39.7) | 11 (16.2) | 15 (22.1) | 29 (42.6) | 24 (35.3) | 5 (7.4) | 10 (14.7) | 29 (42.6) | 24 (35.3) | ||||
| Highest 1/3 | 22 (32.8) | 11 (16.4) | 24 (35.8) | 10 (14.9) | 0.870* | 17 (25.4) | 33 (49.3) | 17 (25.4) | 0.135* | 2 (3.0) | 5 (7.5) | 32 (47.8) | 28 (41.8) | 0.050** | 0 |
| Smoking history | |||||||||||||||
| Never | 12 (46.2) | 5 (19.2) | 7 (26.9) | 2 (7.7) | 1 (3.8) | 10 (38.5) | 15 (57.7) | 1 (3.8) | 7 (26.9) | 11 (42.3) | 7 (26.9) | ||||
| Earlier | 18 (36.7) | 11 (22.4) | 15 (30.6) | 5 (10.2) | 9 (18.4) | 21 (42.9) | 19 (38.8) | 3 (6.1) | 9 (18.4) | 30 (61.2) | 7 (14.3) | ||||
| Currently | 18 (18.8) | 14 (14.6) | 43 (44.8) | 21 (21.9) | <0.001* | 31 (32.3) | 44 (45.8) | 21 (21.9) | <0.001* | 2 (2.1) | 9 (9.4) | 38 (39.6) | 47 (49.0) | 0.001** | 32 |
| Alcohol abuse | |||||||||||||||
| Never | 21 (34.4) | 16 (26.2) | 19 (31.1) | 5 (8.2) | 7 (11.5) | 29 (47.5) | 25 (41.0) | 2 (3.3) | 12 (19.7) | 26 (42.6) | 21 (34.4) | ||||
| Earlier | 6 (25.0) | 5 (20.8) | 8 (33.3) | 5 (20.8) | 8 (33.3) | 11 (45.8) | 5 (20.8) | 1 (4.2) | 1 (4.2) | 11 (45.8) | 11 (45.8) | ||||
| Currently | 7 (18.4) | 2 (5.3) | 20 (52.6) | 9 (23.7) | 0.002* | 15 (39.5) | 15 (39.5) | 8 (21.1) | 0.001* | 1 (2.6) | 3 (7.9) | 19 (50.0) | 15 (39.5) | 0.239** | 72 |
| T class | |||||||||||||||
| T1 | 18 (47.4) | 8 (21.1) | 10 (26.3) | 2 (5.3) | 4 (10.5) | 17 (44.7) | 17 (44.7) | 1 (2.6) | 10 (26.3) | 16 (42.1) | 11 (28.9) | ||||
| T2 | 19 (25.0) | 14 (18.4) | 28 (36.8) | 15 (19.7) | 21 (27.6) | 30 (39.5) | 25 (32.9) | 3 (3.9) | 6 (7.9) | 41 (53.9) | 26 (34.2) | ||||
| T3 | 13 (28.3) | 9 (19.6) | 16 (34.8) | 8 (17.4) | 11 (23.9) | 18 (39.1) | 17 (37.0) | 3 (6.5) | 9 (19.6) | 18 (39.1) | 16 (34.8) | ||||
| T4 | 9 (21.4) | 6 (14.3) | 22 (52.4) | 5 (11.9) | 0.027* | 11 (26.2) | 21 (50.0) | 10 (23.8) | 0.081* | 2 (4.8) | 5 (11.9) | 17 (40.5) | 18 (42.9) | 0.424 ** | 0 |
| N class | |||||||||||||||
| N0–N1 | 14 (21.2) | 9 (13.6) | 32 (48.5) | 11 (16.7) | 22 (33.3) | 31 (47.0) | 13 (19.7) | 3 (4.5) | 10 (15.2) | 25 (37.9) | 28 (42.4) | ||||
| N2–N3 | 45 (33.1) | 28 (20.6) | 44 (32.4) | 19 (14.0) | 0.036* | 25 (18.4) | 55 (40.4) | 56 (41.2) | 0.001* | 6 (4.4) | 20 (14.7) | 67 (49.3) | 43 (31.6) | 0.411* | 0 |
| Stage | |||||||||||||||
| I–II | 5 (16.7) | 3 (10.0) | 15 (50.0) | 7 (23.3) | 12 (40.0) | 14 (46.7) | 4 (13.3) | 0 (0.0) | 3 (10.0) | 14 (46.7) | 13 (43.3) | ||||
| III–IV | 54 (31.4) | 34 (19.8) | 61 (35.5) | 23 (13.4) | 0.019* | 35 (20.3) | 72 (41.9) | 65 (37.8) | 0.003* | 9 (5.2) | 27 (15.7) | 78 (45.3) | 58 (33.7) | 0.117** | 0 |
| Tumor site | |||||||||||||||
| Lateral wall | 39 (33.3) | 27 (23.1) | 34 (29.1) | 17 (14.5) | 21 (17.9) | 52 (44.4) | 44 (37.6) | 5 (4.3) | 20 (17.1) | 60 (51.3) | 32 (27.4) | ||||
| Anterior wall | 18 (29.5) | 8 (13.1) | 30 (49.2) | 5 (8.2) | 15 (24.6) | 22 (36.1) | 24 (39.3) | 4 (6.6) | 8 (13.1) | 23 (37.7) | 26 (42.6) | ||||
| Posterior wall | 0 (0.0) | 0 (0.0) | 2 (66.7) | 1 (33.3) | 1 (33.3) | 2 (66.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (100.0) | ||||
| Superior wall | 2 (9.5) | 2 (9.5) | 10 (47.6) | 7 (33.3) | 0.012** | 10 (47.6) | 10 (47.6) | 1 (4.8) | 0.004** | 0 (0.0) | 2 (9.5) | 9 (42.9) | 10 (47.6) | 0.290** | 0 |
| Grade | |||||||||||||||
| 1 | 1 (5.6) | 2 (11.1) | 9 (50.0) | 6 (33.3) | 7 (38.9) | 8 (44.4) | 3 (16.7) | 1 (5.6) | 1 (5.6) | 7 (38.9) | 9 (50.0) | ||||
| 2 | 10 (12.8) | 13 (16.7) | 35 (44.9) | 20 (25.6) | 21 (26.9) | 42 (53.8) | 15 (19.2) | 2 (2.6) | 11 (14.1) | 35 (44.9) | 30 (38.5) | ||||
| 3 | 48 (45.3) | 22 (20.8) | 32 (30.2) | 4 (3.8) | <0.001* | 19 (17.9) | 36 (34.0) | 51 (48.1) | <0.001* | 6 (5.7) | 18 (17.0) | 50 (47.2) | 32 (30.2) | 0.064** | 0 |
| Treatment | |||||||||||||||
| Sx ± (C)RT | 36 (27.7) | 28 (21.5) | 41 (31.5) | 25 (19.2) | 31 (23.8) | 60 (46.2) | 39 (30.0) | 5 (3.8) | 19 (14.6) | 65 (50.0) | 41 (31.5) | ||||
| (C)RT ± Sx | 23 (31.9) | 9 (12.5) | 35 (48.6) | 5 (6.9) | 0.450* | 16 (22.2) | 26 (36.1) | 30 (41.7) | 0.229* | 4 (5.6) | 11 (15.3) | 27 (37.5) | 30 (41.7) | 0.615* | 0 |
Lateral wall tonsils and tonsillar pillars, Anterior wall base of tongue and vallecula, Superior wall soft palate and uvula
* Chi-square test with asymptotic P value
** Chi-square test with exact P value
a Age groups: lowest 1/3 ≤54.4 years. Middle 1/3 >54.4, <61.6 years. Highest 1/3 ≥61.1 years